Trial | Exclusion criteria | Median (IQR) ASPECTS or infarct volume (mL) of enrolled patients |
MR CLEAN | None | MT+BMM: ASPECTS 9 (7–10) BMM: ASPECTS 9 (8–10) |
Extend IA | Infarct core ≥70 mL | MT+BMM: 12 mL (4–32) BMM: 18 mL (4–29) |
ESCAPE | ASPECTS ≤5 | MT+BMM: ASPECTS 9 (8–10) BMM: ASPECTS 9 (8–10) |
SWIFT PRIME | ASPECTS ≤5 | MT+BMM: ASPECTS 9 (7–10) BMM: ASPECTS 9 (8–10) |
REVASCAT | ASPECTS ≤6 (CT) ASPECTS ≤5 (MRI) | MT+BMM: ASPECTS 7 (6–9) BMM: ASPECTS 8 (6–9) |
THRACE | None | DWI lesion volume: 17 mL (9.2–51.8)* |
PISTE | Hypodensity >1/3 of the MCA territory | MT+BMM: ASPECTS 9 (4–10) BMM: ASPECTS 9 (2–10) |
THERAPY | Hypodensity >1/3 of the MCA territory | MT+BMM: ASPECTS 7.5 (6–9) BMM: ASPECTS 8 (7–9) |
EASI | None | MT+BMM: ASPECTS 8 (7–9) BMM: ASPECTS 9 (8–9) |
DAWN | Infarct core ≥51 mL | MT+BMM: 7.6 mL (2.0–18.0) BMM: 8.9 mL (3.0–18.1) |
DEFUSE-3 | Infarct core ≥70 mL | MT+BMM: 9.4 mL (2.3–25.6) ASPECTS 8 (7–9)† BMM: 10.1 mL (2.1–24.3) ASPECTS 8 (7–9)† |
*Patients in whom the qualifying imaging study was MRI.
†Patients in whom the qualifying imaging study was CT.
ASPECTS, Alberta Stroke Program Early CT Score; BMM, best medical management; MCA, middle cerebral artery; MT, mechanical
thrombectomy; RCT, randomized controlled trial